From GlobeNewswire: 2025-02-25 07:30:00

Kiniksa Pharmaceuticals International, plc reported Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively. ARCALYST 2025 net product revenue is expected to be $560 – $580 million. KPL-387 Phase 2/3 clinical trial in recurrent pericarditis is set to begin in mid-2025. Development of Abiprubart in Sjögren’s Disease will be discontinued. Operating plan remains cash flow positive.

Kiniksa focuses on cardiovascular indications, announcing development of KPL-387 in recurrent pericarditis with monthly dosing. KPL-1161 is also in development for quarterly dosing. Abiprubart development will be halted. Kiniksa terminated its exclusive license agreement for mavrilimumab with MedImmune.

ARCALYST net product revenue was $122.5 million and $417.0 million for Q4 and full year 2024. Over 2,850 prescribers have written ARCALYST prescriptions for recurrent pericarditis. ARCALYST has an average total duration of therapy of approximately 27 months for recurrent pericarditis patients. 13% of the target 14,000 multiple-recurrence patients are actively on ARCALYST treatment.

KPL-387, a monoclonal antibody for recurrent pericarditis, is in Phase 1 trials with potential for monthly dosing. FDA interactions have led to plans to start a Phase 2/3 trial in mid-2025. KPL-1161, another monoclonal antibody, is in IND-enabling development for quarterly dosing.

Financially, Kiniksa reported total revenue of $122.5 million for Q4 2024, with full year revenue at $423.2 million. Operating expenses for Q4 2024 were $141.8 million, with full year expenses at $468.9 million. Net loss for Q4 2024 was $8.9 million, with full year net loss at $43.2 million. Cash, cash equivalents, and short-term investments were $243.6 million as of December 31, 2024.

Kiniksa projects 2025 ARCALYST net product revenue to be between $560 million and $580 million. The company expects its current operating plan to stay cash flow positive annually. A conference call and webcast to discuss financial results and corporate updates are scheduled for 8:30 am ET today.



Read more at GlobeNewswire:: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full